Marquette Asset Management LLC Takes Position in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT)

Marquette Asset Management LLC bought a new stake in Bolt Biotherapeutics, Inc. (NASDAQ:BOLTGet Rating) during the 2nd quarter, Holdings Channel reports. The fund bought 63,779 shares of the company’s stock, valued at approximately $130,000.

Several other hedge funds also recently modified their holdings of BOLT. Suvretta Capital Management LLC boosted its stake in shares of Bolt Biotherapeutics by 68.3% in the 4th quarter. Suvretta Capital Management LLC now owns 2,230,250 shares of the company’s stock valued at $10,928,000 after purchasing an additional 904,750 shares during the last quarter. Renaissance Technologies LLC boosted its stake in shares of Bolt Biotherapeutics by 226.3% in the 1st quarter. Renaissance Technologies LLC now owns 290,100 shares of the company’s stock valued at $795,000 after purchasing an additional 201,200 shares during the last quarter. Echo Street Capital Management LLC bought a new position in shares of Bolt Biotherapeutics in the 1st quarter valued at about $5,493,000. GSA Capital Partners LLP bought a new position in shares of Bolt Biotherapeutics in the 1st quarter valued at about $148,000. Finally, Qube Research & Technologies Ltd boosted its stake in Bolt Biotherapeutics by 204.2% during the 4th quarter. Qube Research & Technologies Ltd now owns 45,640 shares of the company’s stock worth $224,000 after acquiring an additional 30,638 shares during the last quarter. Institutional investors own 69.25% of the company’s stock.

Bolt Biotherapeutics Stock Performance

BOLT stock traded down $0.03 during mid-day trading on Friday, hitting $1.72. 94,084 shares of the company were exchanged, compared to its average volume of 234,240. The company has a debt-to-equity ratio of 0.10, a quick ratio of 9.73 and a current ratio of 9.73. The firm’s 50 day simple moving average is $2.08 and its 200 day simple moving average is $2.15. Bolt Biotherapeutics, Inc. has a 1-year low of $1.39 and a 1-year high of $14.18.

Insiders Place Their Bets

In other Bolt Biotherapeutics news, major shareholder Holdings A/S Novo sold 800,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 13th. The shares were sold at an average price of $2.00, for a total transaction of $1,600,000.00. Following the sale, the insider now directly owns 3,703,991 shares in the company, valued at approximately $7,407,982. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 22.90% of the company’s stock.

Wall Street Analyst Weigh In

Separately, SVB Leerink lowered shares of Bolt Biotherapeutics from an “outperform” rating to a “market perform” rating and reduced their price objective for the stock from $8.00 to $4.00 in a research note on Thursday, August 11th.

About Bolt Biotherapeutics

(Get Rating)

Bolt Biotherapeutics, Inc, a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages.

Featured Stories

Want to see what other hedge funds are holding BOLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bolt Biotherapeutics, Inc. (NASDAQ:BOLTGet Rating).

Institutional Ownership by Quarter for Bolt Biotherapeutics (NASDAQ:BOLT)

Receive News & Ratings for Bolt Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bolt Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.